Benussi, A., Pascual-Leone, A
Qsymia is a formulation of phentermine plus Topamax
WADA Prohibition Status Based on WADAs prohibition categories: GLP3 likely falls under Section S0 (Non-Approved Substances) of the WADA Prohibited List, which includes: Any pharmacological substance not approved by governmental regulatory health authorities for human therapeutic use Drugs under preclinical or clinical development Substances without current regulatory approval from any health authority worldwide Implications for competitive athletes: Prohibited at all times (in-competition and out-of-competition) No Therapeutic Use Exemptions available for unapproved substances Use could result in anti-doping rule violations and sanctions Detection methods under development as clinical trials progress Research Classification: GLP3 is available exclusively for use in FDA-approved clinical trials under Investigational New Drug applications
Most nation-wide pharmacies use the top distributors such as Cardinal and McKesson
Data Source: IRIS by Real Chemistry | Image Credit: Real Chemistry Medicaid coverage for GLP-1s, both for Type 2 diabetes and obesity, varies widely across the United States
Both medications target dual GLP-1/GIP receptors, but only Tirzepatide has FDA approval and is available by prescriptionSurvodutide remains restricted to clinical trial participants
